Photo of Ashwin Sapra

Partner in the General Corporate Practice at the Delhi Office of Cyril Amarchand Mangaldas. With a specialist focus on intellectual property, pharmaceuticals / medical devices regulatory and compliance affairs, Ashwin has an extensive domestic and international experience of 19 years providing advice on matters relating to intellectual property, drug and medical device regulatory and compliance affairs, transactional affairs, anti corruption and anti kick back laws, litigation and dispute resolution. He can be reached at ashwin.sapra@cyrilshroff.com

This is the third post in the our new blog series on the Budget 2018. Following our earlier posts (here, here and here) on the impact of the Budget on the Direct and Indirect Tax regimes, this piece focuses on the initiatives proposed under this Budget in the Healthcare sector. We hope you enjoy reading this as much as we have enjoyed putting this together.


A healthcare focused Budget. Universal healthcare on the anvil.

“India cannot realise its demographic dividend without its citizens being healthy”…. Mr. Arun Jaitley, Hon’ble Finance Minister of India in his budget speech of February 1, 2018.

One of the key constituents of the Union Budget for the year 2018-2019 is healthcare. With the Budget envisaging a boost to the healthcare insurance, service provider and pharmaceutical sector, share prices of some key pharmaceutical companies showed a spike during the speech.

The Hon’ble Finance Minister announced two new initiatives under the “Ayushman Bharat Programme“:

Continue Reading First Impressions of the Budget 2018 – Healthcare, Pharmaceuticals and Life Sciences